Literature DB >> 24206933

Executive functioning in context: Relevance for treatment and monitoring of phenylketonuria.

Stephan C J Huijbregts1, Rosa Gassió, Jaume Campistol.   

Abstract

This paper presents findings from studies of EF in individuals with early-treated PKU within the context of recent advances in neuropsychological theory and research. It focuses on means of assessment, contexts of assessment, and the best way to define and investigate EF. Several conclusions can be drawn based on the findings presented here. The first conclusion is that there is clear evidence for phenylalanine-related EF-deficits in early-treated PKU, particularly with respect to prepotent response inhibition and the manipulation or monitoring component of working memory. An important note, however, is that measurement of EF in PKU has become too fragmented, as different researchers and clinicians use different definitions of EF, and subsequently, different instruments to measure EF. This appears to be one of the most important causes of mixed results. A second conclusion is that there appears to be a need to incorporate at least one specific, relatively new taxonomy of EF in PKU-research, i.e. the taxonomy that distinguishes hot and cool EFs, where hot EF is associated with regulation of affect/emotions and motivation, or regulatory functions when the context contains such elements, while cool EF concerns decontextualized regulatory abilities. PKU in adults is increasingly associated with different mental health problems, despite supposedly good treatment standards and adherence throughout childhood and adolescence. Since hot EF is strongly associated with such mental health problems, it is recommended that the hot-cool taxonomy will feature more prominently in future PKU-studies.
© 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Executive function; Hot and cool executive functions; Inhibitory control; Mental health; Phenylketonuria; Working memory

Mesh:

Substances:

Year:  2013        PMID: 24206933     DOI: 10.1016/j.ymgme.2013.10.001

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  8 in total

1.  Characterization of phenylalanine hydroxylase gene mutations in phenylketonuria in Xinjiang of China.

Authors:  Wuzhong Yu; Jiang He; Xi Yang; Hongyun Zou; Junhao Gui; Rui Wang; Liu Yang; Zheng Wang; Quan Lei
Journal:  Int J Clin Exp Med       Date:  2014-11-15

2.  Blood phenylalanine reduction corrects CNS dopamine and serotonin deficiencies and partially improves behavioral performance in adult phenylketonuric mice.

Authors:  Shelley R Winn; Tanja Scherer; Beat Thöny; Ming Ying; Aurora Martinez; Sydney Weber; Jacob Raber; Cary O Harding
Journal:  Mol Genet Metab       Date:  2017-10-19       Impact factor: 4.797

3.  Treatment adherence in tyrosinemia type 1 patients.

Authors:  Domingo González-Lamuño; Paula Sánchez-Pintos; Fernando Andrade; María L Couce; Luís Aldámiz-Echevarría
Journal:  Orphanet J Rare Dis       Date:  2021-06-03       Impact factor: 4.123

4.  Acute exercise in treated phenylketonuria patients: Physical activity and biochemical response.

Authors:  Priscila Nicolao Mazzola; Bruno Costa Teixeira; Gabriel Henrique Schirmbeck; Alvaro Reischak-Oliveira; Terry G J Derks; Francjan J van Spronsen; Carlos Severo Dutra-Filho; Ida Vanessa Doederlein Schwartz
Journal:  Mol Genet Metab Rep       Date:  2015-10-22

5.  Large Neutral Amino Acids (LNAAs) Supplementation Improves Neuropsychological Performances in Adult Patients with Phenylketonuria.

Authors:  Iris Scala; Maria Pia Riccio; Maria Marino; Carmela Bravaccio; Giancarlo Parenti; Pietro Strisciuglio
Journal:  Nutrients       Date:  2020-04-15       Impact factor: 5.717

6.  Beneficial Effects of Slow-Release Large Neutral Amino Acids after a Phenylalanine Oral Load in Patients with Phenylketonuria.

Authors:  Iris Scala; Daniela Concolino; Anna Nastasi; Giulia Esposito; Daniela Crisci; Simona Sestito; Stefania Ferraro; Lucia Albano; Margherita Ruoppolo; Giancarlo Parenti; Pietro Strisciuglio
Journal:  Nutrients       Date:  2021-11-10       Impact factor: 5.717

7.  Intellectual and Developmental Status in Children With Hyperphenylalaninemia and PKU Who Were Screened in a National Program.

Authors:  Parisa Aghasi; Arya Setoodeh; Azadeh Sayarifard; Maryam Rashidiyan; Fatemeh Sayarifard; Ali Rabbani; Javad Mahmoudi-Gharaei
Journal:  Iran J Pediatr       Date:  2015-12-23       Impact factor: 0.364

8.  White and gray matter brain development in children and young adults with phenylketonuria.

Authors:  Zoë Hawks; Anna M Hood; Dov B Lerman-Sinkoff; Joshua S Shimony; Jerrel Rutlin; Daniel Lagoni; Dorothy K Grange; Desirée A White
Journal:  Neuroimage Clin       Date:  2019-07-02       Impact factor: 4.881

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.